High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin
therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily)
in HIV-infected persons taking antiretroviral therapy (ART) who have coronary heart disease
(CHD).